rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively.
|
21884820 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF revealed preferential antiproliferative activity against BRAF(V600E) mutant cells in vitro, in contrast to the use of shRNA-mediated knockdown of BRAF, which inhibited cell growth of glioma cell lines regardless of BRAF mutation status.
|
22038996 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF revealed preferential antiproliferative activity against BRAF(V600E) mutant cells in vitro, in contrast to the use of shRNA-mediated knockdown of BRAF, which inhibited cell growth of glioma cell lines regardless of BRAF mutation status.
|
22038996 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively.
|
21884820 |
2011 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anaplastic feature was suggested based on the association of some pathological feature (eosinophilic granular bodies, reticulin network and diffuse CD34 expression) and the BRAF V600E mutation.
|
24857351 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs.
|
23822828 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and increased G0/G1 arrest in glioma cells with BRAF-V600E.
|
24721513 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and increased G0/G1 arrest in glioma cells with BRAF-V600E.
|
24721513 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anaplastic feature was suggested based on the association of some pathological feature (eosinophilic granular bodies, reticulin network and diffuse CD34 expression) and the BRAF V600E mutation.
|
24857351 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs.
|
23822828 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
|
28727518 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
|
28727518 |
2017 |